AUTHOR=Bouter Caroline , Henniges Philipp , Franke Timon N. , Irwin Caroline , Sahlmann Carsten Oliver , Sichler Marius E. , Beindorff Nicola , Bayer Thomas A. , Bouter Yvonne 

TITLE=18F-FDG-PET Detects Drastic Changes in Brain Metabolism in the Tg4–42 Model of Alzheimer’s Disease

JOURNAL=Frontiers in Aging Neuroscience

VOLUME=10

YEAR=2019

URL=https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2018.00425

DOI=10.3389/fnagi.2018.00425

ISSN=1663-4365

ABSTRACT=<p>The evaluation of new therapeutic strategies in Alzheimer’s disease (AD) relies heavily on <italic>in vivo</italic> imaging and suitable animal models that mimic the pathological changes seen in patients. <sup>18</sup>F-Fluorodeoxyglucose (<sup>18</sup>F-FDG)-positron-emission tomography (PET) is a well-established non-invasive imaging tool for monitoring changes in cerebral brain glucose metabolism <italic>in vivo</italic>. <sup>18</sup>F-FDG-PET is used as a functional biomarker for AD as patients show an early and progressive reduction of cerebral glucose metabolism. However, earlier studies in preclinical models of AD showed conflicting results. The aim of this study was the evaluation of cerebral glucose metabolism in the Tg4–42 mouse model of AD using <sup>18</sup>F-FDG-PET/magnetic resonance imaging (MRI). Tg4–42 mice show an age-dependent reduction in glucose metabolism together with severe neuron loss and memory deficits. Similar to AD patients early decrease in <sup>18</sup>F-FDG uptake was already detected in young (3 months) Tg4–42 mice. The altered glucose metabolism coupled with age- and disease related cognitive decline of Tg4–42 mice make it a well-suited model for preclinical testing of AD-relevant therapeutics.</p>